LGW16-03

Phase 1Small molecule

EEric R. Henderson

LGW16-03 is one of 4 small molecule programs targeting Adults. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdultsRecruiting

AdultsPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Adults

#DrugCompanyPhaseTrials

Nourianz

Kyowa Kirin Co., Ltd.

Preclinical

1 2

Psilocybin

COMPASS Pathways

Phase 1

—3

AB-Free Kava

UUniversity of Florida

Phase 1

1 4

LGW16-03

EEric R. Henderson

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Adults

NCT07385430

Clinical

Trials by Indication[1]

Adults1 trial

Phase 1 Study of LGW16-03 To Identify Nerves

Recruiting·EEric R. Henderson·Phase 1·NCT07385430·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LGW16-03. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LGW16-03 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LGW16-03. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eric R. Henderson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EEric R. Henderson

LGW16-03

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Adults1 trial

References

Drug Info

Quick Facts

Related News